HIMS Stock Jumps Overnight: CEO Eyes Heart Attack Prediction Firm With ‘Unreal’ Value

• Hims is expanding beyond telehealth with a push into hormone care, while building out at-home testing and virtual care services.
• Peptides is also seen as the next growth driver, with Bank of America Securities flagging upside from upcoming FDA reviews that could open new revenue streams.
• Hims has recently moved towards branded drugs via Novo Nordisk and Eli Lilly partnerships.

Shares of Hims & Hers Health, Inc. (HIMS) jumped more than 1% overnight heading into Monday after CEO Andrew Dudum expressed interest in a firm claiming 86% accuracy in predicting heart attacks, after an investor flagged the tech as having “unreal value.”

HIMS stock ended 1% higher on Friday, with a marginal after-hours gain. 

CEO Hints At Interest in Heart Test Firm 

Dudum responded with a brief “Message me” to a post on X by Conor Neu, chief investment officer at Pier Asset Management. Neu said that he was “personally invested in a company that can tell you whether you will have a heart attack in the next 12 months. With 86% certainty. From a blood test.” 

He added that it was “weak at scaling” and urged that “someone please buy this and take it to the masses.”

The comments come as Hims continues broadening its scope beyond telehealth prescriptions into more integrated healthcare offerings. Hims has recently been building out its hormone health business as a key growth area. The company launched Testosterone Rx+ last week, a once-daily pill that naturally increases testosterone levels. 

It builds on treatments introduced in September 2025 that use the Enclomiphene drug, which helps the body naturally produce its own testosterone while maintaining fertility. The company also added combination options that include Tadalafil, a medication commonly used to treat erectile dysfunction, for men with low testosterone.

Testosterone Rx+ brings these elements together in a single pill, combining Enclomiphene with zinc, vitamins B6 and B12, and L-arginine, an amino acid that supports blood flow. According to the company, 95% of users saw their testosterone levels increase, with 80% reaching healthy levels within about two months.

The program includes symptom screening, at-home lab testing and virtual care, reflecting a broader push toward continuous, data-driven treatment. Hims has also expanded its women’s health offerings with estrogen patch treatments for menopause and perimenopause.

Peptides Upside Fuels HIMS Shares

Investor focus has recently shifted toward peptides as a potential new revenue driver. Last month, Bank of America Securities (BofA) called an upside for HIMS shares from upcoming FDA discussions between July 23 and July 24 to review several peptide substances for possible inclusion on the 503A Bulks List, which determines which ingredients can be used for compounded medications.

BofA said the move could open new revenue opportunities and allow Hims to repurpose existing GLP-1 infrastructure toward peptide therapies. The firm also raised its valuation multiple assumption to 25.5x from 21.5x, though it noted that the review is only an initial step and not a guarantee of approval. 

The review follows a 2023 decision to restrict nearly 20 peptide substances due to safety concerns, including potential risks related to cancer and organ damage.

HIMS Faces GLP-1 Pressure 

The telehealth firm’s expansion into newer categories comes as regulatory scrutiny intensifies in the weight-loss drug market. The U.S. Food and Drug Administration (FDA) recently proposed restricting compounding of key GLP-1 ingredients such as Semaglutide and Tirzepatide, limiting the availability of lower-cost alternatives.

Hims has already started shifting towards branded therapies through partnerships with Novo Nordisk and Eli Lilly, offering treatments including Wegovy, Ozempic, Zepbound and Mounjaro. The company has also launched waitlists for some of these drugs and introduced tiered pricing through its platform.

Dudum previously compared the approach to Netflix’s early days, saying the focus is on expanding choice rather than relying on a single therapy. He had also said that Hims has already begun shipping Novo Nordisk medicines and expects to exceed a run rate of 100,000 Wegovy prescriptions per month.

How Do Retail Traders Feel About HIMS?

On Stocktwits, retail sentiment for HIMS slipped to ‘bearish’ from ‘bullish’ levels a week ago amid ‘low’ message volume.

HIMS has declined 24% over the past year. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: CVKD Stock Retail Sentiment Peaks After FDA Clears Phase 3 Path For Blood Clot Drug